^
Association details:
| Biomarker: | SLFN11 overexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response
Published date:
03/15/2023
Excerpt:
Lurbinectedin is highly effective in all molecular subtypes of SCLC in vitro and in vivo, with IC50 values at least two logs more potent than for other antitumoral agents and its activity is even greater in tumors with high POU2F3 expression and/or high SLFN11 expression.
Source:
Title:
2145 / 19 - High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models
Published date:
03/15/2023
Excerpt:
Cell viability assays in 13 SCLC models confirm high SLFN11 expressing cell lines are 4-fold more sensitive to lurbinectedin compared to low SLFN11 expressing cell lines (ΔpIC50 = 0.64; p = 0.0451).
Source:
Title:
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
Published date:
11/01/2021
Excerpt:
Among 21 human SCLC cell lines...cell lines with high expression of Schlafen-11 (SLFN11) protein, a promising biomarker of response to other DNA damaging agents (e.g., chemotherapy, PARP inhibitors), were more sensitive to single-agent lurbinectedin (FC =3.2, P=0.005). SLFN11 was validated as a biomarker of sensitivity to lurbinectedin....As shown in Figure 1C, cell lines with higher SLFN11 expression (bimodal separation by RPPA) were significantly more sensitive to lurbinectedin (P=0.006, FC=3.26)…. In DMS79 xenografts that have high SLFN11 expression, lurbinectedin treatment significantly reduced tumor growth as compared to vehicle (Figure 1G).
DOI:
doi: 10.21037/tlcr-21-437
